San Jose, CA, United States of America

David Bellovin

This inventor holds 13 USPTO granted patents and 10 published patent applications and 4 EPO patents, primarily in Cancer Immunotherapy. Top assignees: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Compnay, Adimab, LLC. Active years: 2017-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David Bellovin. Retrieved from https://idiyas.com/inventor/david-bellovin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 13 

% Patents Active = 92.3

 

Average Co-Inventor Count = 6.2

ph-index = 3

Forward Citations = 30(Granted Patents)


Location History:

  • South San Francisco, CA (US) (2017 - 2019)
  • San Jose, CA (US) (2019 - 2023)

Company Filing History:


Years Active: 2017-2026

Loading Chart...
Loading Chart...
Areas of Expertise:
B7-H4 Antibodies
CD80 Polypeptides
CSF1R Therapy
PD-1 Antibodies
Combination Therapy
Cancer Treatment
Mesothelioma
FGFR1 ECD
Antibody Methods
Polypeptide Use
Immunotherapy
13 patents (USPTO):Explore Patents

Title: The Innovative Journey of David Bellovin: Pioneering Technology and Cybersecurity.

Introduction:

David Bellovin, a dedicated inventor hailing from San Jose, CA, has left an indelible mark on the digital landscape through his groundbreaking innovations in technology and cybersecurity. With 11 patents to his name, his contributions have reshaped the industry for years to come.

Latest Patents:

Among his latest patents is the development of B7-H4 antibodies and methods of use thereof. These antibodies exhibit specificity in binding to human B7-H4, with potential applications in enhancing T cell proliferation, increasing interferon-gamma production, and depleting B7-H4 expressing cells, particularly in the treatment of disorders like cancer. Additionally, Bellovin has also ventured into the realm of cancer treatment with the development of an anti-CSF1R antibody and anti-PD-1 antibody combination therapy, offering promising approaches to combat selected cancers.

Career Highlights:

Throughout his career, David Bellovin has lent his expertise to notable companies such as Five Prime Therapeutics, Inc. and Bristol-Myers Squibb Company (rephrased for readability). His innovative spirit and relentless pursuit of excellence have not only shaped his own journey but have also influenced the trajectories of the organizations he has been a part of.

Collaborations:

In his quest for pioneering solutions, Bellovin has collaborated with esteemed professionals in the field, including coworkers like Brian Wong and Emma Masteller. Together, they have synergized their efforts to drive forward advancements in technology and cybersecurity, creating a ripple effect in the industry.

Conclusion:

David Bellovin's unwavering commitment to innovation and his profound impact on technology and cybersecurity underscore his status as a true trailblazer in the field. His patents stand as a testament to his ingenuity, while his collaborations and career highlights reflect a journey marked by dedication and excellence, shaping the digital landscape for generations to come.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…